The 23andMe Experience - A Lot of Knowledge is of Little Help?
By Alison Lashwood,
BioNews
| 02. 23. 2015
Untitled Document
The 23andMe test and other similar direct-to-consumer (DTC) genetic tests are likely here to stay. Those in favour see them as a way of engaging the public with science and making it fun, but there are problematic aspects, too. The issue of interpretation of the results is perhaps of greatest concern.
In BioNews 788, Professor Joyce Harper highlights some of the issues that the general public need to be aware of should they undertake such testing.
Read more...
Related Articles
By Stephanie Pappas, LiveScience | 01.15.2026
Genetic variants believed to cause blindness in nearly everyone who carries them actually lead to vision loss less than 30% of the time, new research finds.
The study challenges the concept of Mendelian diseases, or diseases and disorders attributed to...
By David Cox, Wired | 01.05.2026
As he addressed an audience of virologists from China, Australia, and Singapore at October’s Pandemic Research Alliance Symposium, Wei Zhao introduced an eye-catching idea.
The gene-editing technology Crispr is best known for delivering groundbreaking new therapies for rare diseases, tweaking...
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
